Dataset Information

Follow-Up Adherence After Treatment With Curative Intent for Stage II and III Colorectal Cancer Patients.

ABSTRACT:

Introduction

After colorectal cancer (CRC) treatment, patients undergo five-year follow-up involving carcinoembryonic antigen (CEA) tests, imaging, and colonoscopies. This retrospective cohort study explores adherence to the CRC follow-up guideline in the Netherlands until 2021 and its association with treatment of recurrences with curative intent.

Methods

Stage II/III CRC patients with recurrent disease within 3 years after diagnosis were selected from the Netherlands Cancer Registry (n = 430). Adherence to CEA tests, imaging, and colonoscopy was classified as 'according to/more follow-up' or 'less follow-up' than recommended. Logistic regression analyses examined factors associated with receiving less follow-up and the relationship between 'follow-up adherence' and 'treatment with curative intent', potentially mediated by 'mode of detection' (symptomatically vs. routine test).

Results

In total, 18.3% patients had fewer CEA tests, 41.4% fewer imaging, and 56.1% fewer colonoscopies than recommended. Factors associated with fewer follow-up moments were tumor localization, age (≥ 75 years), comorbidities, tumor differentiation and adjuvant chemotherapy. Patients receiving fewer CEA tests faced 4.8 times higher odds (95% CI: 2.9-8.1) of symptom-detected recurrence and were less likely to be curatively treated (OR = 0.5; 95% CI: 0.3-0.9). Mediation analysis indicated a significant average causal mediation effect (p = 0.003), emphasizing the mediating role of mode of detection. Receiving fewer imaging and colonoscopies showed insignificant total effects on treatment with curative intent.

Conclusion

Our findings offer insights into follow-up adherence, detection mode, and treatment with curative intent. The discovery that adherence was highest for CEA, along with the correlation between CEA adherence and treatment with curative intent, aligns with the recent adaptation of guidelines emphasizing CEA measurement over imaging.

SUBMITTER: Boute TC

PROVIDER: S-EPMC11865713 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Follow-Up Adherence After Treatment With Curative Intent for Stage II and III Colorectal Cancer Patients.

Boute Tara C TC van Eekelen Rik R Elferink Marloes A G MAG Birgit Lissenberg Witte LW de Wilt Johannes H W JHW Vink Geraldine R GR Greuter Marjolein J E MJE Coupé Veerle M H VMH

Cancer medicine 20250301 5

<h4>Introduction</h4>After colorectal cancer (CRC) treatment, patients undergo five-year follow-up involving carcinoembryonic antigen (CEA) tests, imaging, and colonoscopies. This retrospective cohort study explores adherence to the CRC follow-up guideline in the Netherlands until 2021 and its association with treatment of recurrences with curative intent.<h4>Methods</h4>Stage II/III CRC patients with recurrent disease within 3 years after diagnosis were selected from the Netherlands Cancer Regi ...[more]

PMID: 40013322

Similar Datasets

Project description:Distant metastasis is the major causes of death in colorectal cancer (CRC) patients. In order to identify genes influencing the prognosis of patients with CRC, we compared gene expression in primary tumors with and without distant metastasis using an oligonucleotide microarray. We also examined the expression of the candidate gene in 100 CRC patients by quantitative real-time reverse transcription PCR and studied the relationship between its expression and the prognosis of patients with CRC. As a result, we identified MUC12 as a candidate gene involved in metastasis processes by microarray analysis. Quantitative real-time reverse transcription PCR showed that MUC12 expression was significantly lower in cancer tissues than in adjacent normal tissues (P < 0.001). In stage II and stage III CRC, patients with low expression showed worse disease-free survival (P = 0.038). Multivariate analysis disclosed that MUC12 expression status was an independent prognostic factor in stage II and stage III CRC (relative risk, 9.532; 95% confidence interval, 2.303-41.905; P = 0.002). This study revealed the prognostic value of MUC12 expression in CRC patients. Moreover, our result suggests MUC12 expression is a possible candidate gene for assessing postoperative adjuvant therapy for CRC patients. Total of 111 microarray datasets (77 for LCM samples, and 17 pairs for homogenized samples from tumor and adjacent tissues) were normalized using robust multi-array average (RMA) method under R 2.6.2 statistical software together with BioConductor package, as described previously. Then, the gene expression levels were log2-transformed, and 62 control probe sets were removed for further analysis. In order to identify a set of genes associated with development of metastatic recurrence, we performed Wilcoxon rank-sum test for gene expression differences of 54,613 probe sets between recurrence and non-recurrence groups. Similarly, Wilcoxon singed-rank test was conducted to select genes which showed significant expression difference between tumor and adjacent tissue. Then, we selected a set of genes that satisfied both of above two criteria.

Dataset Information

Follow-Up Adherence After Treatment With Curative Intent for Stage II and III Colorectal Cancer Patients.

Introduction

Methods

Results

Conclusion

Publications

Follow-Up Adherence After Treatment With Curative Intent for Stage II and III Colorectal Cancer Patients.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets